

BIBLIOGRAPHY

1. William F. Ganong. Review of Medical Physiology, 21st edn. Endocrine functions of the pancreas and regulation of carbohydrate metabolism. 1999 : 336, 339.
2. Ralph A. De Fronzo. Pathogenesis of type-2 diabetes mellitus. Med Clin N Am 2004 ; 88 : 787-835.
3. The diabetes control and complications trial research group. Lifetime benefits and costs of intensive therapy as practice in the diabetes control and complication trail. JAMA 1996; 276: 1409-15.
4. American Diabetes Association consensus on self monitoring of blood glucose diabetes care 1987 ; 10 : 95-9. Harris MI,Cowie CC,Howie LJ.
5. Daneman D, Siminera L. The role of self monitoring of blood glucose in the routine management of children with insulin dependent diabetes mellitus. Diabetes care 1985 ; 8 : 1 -4.
6. Berry H. Ginsberg. Less invasive technology. Clin Chem 1992 ; 38(9) : 1596-1600.
7. Pohl SI, Gonder-Fredrick LA. self measurement of blood glucose concentrations. Clinical significance of patient generated measurements. Diabetic Care 1985 ; 8 : 617-9.
8. Omar S, Khalil. Sterioscopic and clinical aspects of non invasive glucose measurements. Clinical chemistry 1999 ; 45 (2) : 165-177.
9. S. Amer, M. Yousuf, P. Q. Siddqui, and J. Alam. Salivary glucose concentrations in patients with diabetes mellitus— a Journal of Biomedicine and Biotechnology

- minimally invasive technique for monitoring blood glucose levels. *Pakistan Journal of Pharmaceutical Sciences*, 2001; 14(1) : 33-37.
10. NIH Publication:No:04-4551Oct:2003 <http://diabetes.nidk.nih.gov/dm/pubs/glucosemonitor/index.htm>
 11. <http://www.mydr.com.au/tests-investigations/diabetes-and-urine-glucose-monitoring>
 12. BH Ginsberg An overview of minimally invasive technologies. *Clin Chem* 1992 ; 38(11) : 2360 .
 13. Siliva Chiappin, Giorgia Antonelli, Rasalba Gatti, Elio F De Palo. Saliva specimen : A new laboratory tool for diagnostic and basic investigation. *Clinica Chimica Acta* 2007 ; 383 (1 – 2) : 30-40.
 14. Eliasz Kaufman and Ira B. Lamster. The diagnostic applications of saliva-A review. *Crit rev Oral Biol Med* 2002 ; 13(12):197-212.
 15. K. K. Mehrotra, T. N. Chawla, and A. Kumar, Correlation of salivary sugar with blood sugar. *Journal of the Indian Dental Association*, 1968 ; 40(10) : 265–269.
 16. C. O. Reuterving, G. Reuterving, E. H'agg, and T. Ericson. Salivary flow rate and salivary glucose concentration in patients with diabetes mellitus influence of severity of diabetes. 1987 ; 13(4) : 457–462.
 17. P. Marchetti, M. Tognarelli, R. Giannarelli. Decreased salivary glucose secretory rate: usefulness for detection of diabetic patients with autonomic neuropathy. *Diabetes Research and Clinical Practice* 1989 ; 7(3) : 181–186.
 18. Huizinga MM, Rothman RL. Addressing the diabetes pandemic: A comprehensive approach. *Indian J Med Res* 2006; 124 : 481-4.

19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27 : 1047-53.
20. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. *Diabetes Atlas*. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006 p. 15-103.
21. Ahuja MMS. Epidemiological studies on diabetes mellitus in India. In: Ahuja MMS, editor. *Epidemiology of diabetes in developing countries*. New Delhi: Interprint; 1979 p. 29-38.
22. Ramachandran A, Jali MV, Mohan V, Snehalatha C, Viswanathan M. High prevalence of diabetes in an urban population in south India. *BMJ* 1988; 297 : 587-90.
23. Sridhar GR, Rao PV, Ahuja MMS. Epidemiology of diabetes and its complications. In: *RSSDI textbook of diabetes mellitus*. Hyderabad: Research Society for the Study of Diabetes in India ; 2002 p. 95-112.
24. Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M. Prevalence of glucose intolerance in Asian Indians. Urban-rural difference and significance of upper body adiposity. *Diabetes Care* 1992; 15 : 1348-55.
25. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence of NIDDM in an urban population in India. *Diabetologia* 1997; 40 : 232-7.
26. V. Mohan, S. Sandeep, R. Deepa, B. Shah and C. Varghese. Epidemiology of type 2 diabetes: Indian scenario. *Indian J Med Res* 2007 ; 125 : 217-230.

27. Kutty VR, Soman CR, Joseph A, Pisharody R, Vijayakumar K. Type 2 diabetes in southern Kerala. Variation in prevalence among geographic divisions within a region. *Natl Med J India* 2000; 13 : 287-92.
28. Ramachandran A, Snehalatha C, Vijay V, King H. Impact of poverty on the prevalence of diabetes and its complications in urban southern India. *Diabet Med* 2002; 19 : 130-5.
29. Chen Y.T. and A. Burchell. "Glycogen storage diseases." In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (eds.), *The Metabolic Basis of Inherited Disease*, 7th edition. New York: McGrawHill, 1995.
30. Cornblath M. and R. Schwartz. "Disorders of glycogen metabolism." In M. Cornblath and R. Schwartz, *Disorders of Carbohydrate Metabolism in Infancy*, 3rd edition. Cambridge: Blackwell 1991.
31. Stryer, L. *Biochemistry*, 4th edition. New York: W. H. Freeman, 1995.
32. [http://www.scribd.com/dc/345623/The cori cycle.](http://www.scribd.com/dc/345623/The%20cori%20cycle)
33. Improvement in glycemic excursions with a transcutaneous, real time continuous glucose sensor. A randomized controlled trial. *Diabetes Care* 2006 ; 29(1) : 44-50. Satish Garg, Howard Zisser, Sherwyn Schwartz, Timothy Bailey, Roy Kaplan, Samuel Ellis, Lois Jovanovic.
34. Kumar, Cotran, Robbins. *Robins's Basic Pathology*. 7th edition. Elsevier publication. New Delhi. 2003.
35. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. *Lancet* 1991; 337 : 382-6.

36. Mohan V, Sharp PS, Cloke HR, Burrin JM, Schumer B, Kohner EM. Serum immunoreactive insulin responses to aglucose load in Asian Indian and European Type 2 (noninsulin- dependent) diabetic patients and control subjects. *Diabetologia* 1986; 29 : 235-7.
37. Abate N, Chandalia M. Ethnicity and type 2 diabetes: focus on Asian Indians. *J Diabetes Complications* 2001; 15 :320-7.
38. Misra A. Pandey RM, Devi JR, Sharma R, Vikram NK, Khanna N. High prevalence of diabetes, obesity and dislipidemia in urban slum population in northern India. *Int. Journal of Obes Relat Metab Disord* 2001 ; 25 : 1722-9.
39. American Diabetes Association (ADA). Standards of medical care in diabetes 2009. *Diabetes Care*. 2009; 32 :S13-S61.
40. American Diabetes Association, clinical practice recommendations in diabetes, *Diabetes Care*, 2004 ; 27, S1-148.
41. care.diabetesjournals.org. *Diabetes Care*. 2010 ; 33 : S1.
42. Engelgau MM, Narayan KM, HermanWH. Screening for type 2 diabetes. *Diabetes Care* 2000 ; 23:1563–1580.
43. American diabetes Association Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997 ; 20:1183–11975.
44. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women 1999–2005. *Diabetes Care* 2008 ; 31 : 899–904.

45. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care* 2002 ; 25:1862–1868.
46. Tuomilehto J, Lindstroöm J, Eriksson JG, Valle TT, Haama-laïnen H, Ilanne-Parikka P, Keinaïnen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucosetolerance. *N Engl J Med* 2001 ; 344 : 1343–1350.
47. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, CaoZheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;20:537–544.
48. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006 ; 49 : 289–297.
49. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 2007;30:753–759.
50. American Diabetes Association: Consensus statement on self-monitoring of blood glucose. *Diabetes Care* Jan 1987;10:95–99.

51. Molitch ME, Barr J, Callahan PL, Campbell RK, Delahanty LM, Rizza R et al, American Diabetes Association: Self monitoring of blood glucose. *Diabetes Care* 1994;17:81–86.
52. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. *Diabetes Care* 2005; 28:1510–1517.
53. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2002;48:436–472.
54. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Beck RW, Hirsch IB, Laffe L, Tamborlane WV, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O’Grady M, Ruedy KJ, Tansey M, Tsailikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D.: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. *Diabetes Care* 2009;32:1378– 1383.
55. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000 ; 321 : 405–412.
56. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. *Diabetes Care* 1999;22:1785–1789.

57. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008 ; 31 : 1473–1478.
58. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. *Diabetes Care* 2002;25:275–278.
59. Wilson DM, Kollman. Diabetes Research in Children Network (DirecNet) Study Group, Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. *Diabetes Care* 2008;31:381–385.
60. Ohkubo Y, Kishikawa H, Araki E, MiyataT, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin. Microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28:103–117.
61. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:854–865.
62. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–853.

63. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008 ; 358 : 2560–2572.
64. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA : 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008 ; 359:1577–1589.
65. Skyler Jay S, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM. et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of thACCORD, ADVANCE, and VA Diabetes trials. A positional statement of American Diabetes Association and a scientific statement of the American college of cardiology foundation and the American Heart association.. *Diabetes Care* 2009;32 (1):187–192.
66. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2006;29:1963– 1972.
67. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32:193–203.

68. Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes—2006. *Diabetes Care* 2006;29:2140–215.
69. DAFNE Study Group. Training in flexible– flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating.(DAFNE)randomized controlled trial. *BMJ* 2002;325:1-6.
70. Goldhaber-Fiebert JD, Goldhaber-Fiebert SN, Tristaín ML, Nathan DM. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetic patients in rural Costa Rica. *Diabetes Care* 2003;26:24–29.
71. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, Lau J. Longterm effectiveness of weight-loss interventions in adults with pre-diabetes: a review. *Am J Prev Med* 2005;28:126–139.
72. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. American Diabetes Association, North American Association for the Study of Obesity, American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association. *Diabetes Care* 2004;27:2067–2073.
73. Wolf AM, Conaway MR, Crowther JQ, Hazen KY, L Nadler J, Oneida B, Bovbjerg VE. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. *Diabetes Care* 2004; 27:1570–1576.

74. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and metaanalysis of weight-loss clinical trials with a minimum 1-year follow-up. *J Am Diet Assoc* 2007;107:1755–1767.
75. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl J Med* 2002;346:393–403.
76. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM. et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. *Diabetes Care* 2007;30:1374–1383.
77. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS. et al. A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 2003;348:2082–2090.
78. Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR. et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women. *JAMA* 2007;297:969–977.
79. Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J. et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. *Ann Intern Med* 2004;140: 778–785.

80. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr, Brehm BJ, et al. Effects of low-carbohydrates low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med* ;166:285–293.
81. Buchwald H, Estok R, Fahrenbach K, Banel D, Jensen MD, Pories WJ. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med* 2009;122:248–256.
82. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S. et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. *JAMA* 2008;299:316–323.
83. Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B. et al. National standards for diabetes self-management education. *Diabetes Care* 2007;30: 1630–1637.
84. Mulcahy K, Maryniuk M, Peeples M, Peyrot M, Tomky D, Weaver T. et al. Diabetes self-management education core outcomes measures. *Diabetes Educ* 29:768-2003;84:787.
85. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. *Diabetes Care* 2001;24:561–587.
86. Robbins JM, Thatcher GE, Webb DA, Valdmanis VG. Nutritionist visits, diabetes classes, and hospitalization rates and charges: the Urban Diabetes Study. *Diabetes Care* 2008;31:655–660.

87. Duncan I, Birkmeyer C, Coughlin S, Li QE, Sherr D, Boren S. Assessing the value of diabetes education. *Diabetes Educ* 2009;35:752–760.
88. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity / exercise and type 2 diabetes. *Diabetes Care* 2004;27:2518–2539.
89. U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Atlanta, GA, Centers for Disease Control and Prevention, 2008.
90. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. ADA. Screening for coronary artery disease in patients with diabetes. *Diabetes Care* 2007;30:2729–2736.
91. Berger M, Berchtold P, Cuppers HJ, Drost H, Kley HK, Muller WA. et al. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. *Diabetologia* 1977;13:355–365.
92. Fisher L, Skaff MM, Mullan JT, Arean P, Mohr D, Masharani U. et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. *Diabetes Care* 2007;30:542–548.
93. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. *Diabetologia* 2002;45:937–948.
94. Cryer PE, Davis SN, Shamon H. Hypoglycemia in diabetes. *Diabetes Care* 2003;26:1902–1912.
95. (<http://www.cdc.gov/vaccines/recs/>).
96. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R. et al. American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from

- the American Heart Association and the American Diabetes Association. *Diabetes Care* 2007;30:162–172.
97. Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 1996;335:257–265.
98. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267–1278.
99. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 2006;29:1478–1485.
100. Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003;361:2005–2016.
101. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA* 2007;297:2018–2024
102. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. *Diabetes Care* 1999;22:1887–1898.

103. UK prospective Diabetes Study(UKPDS) group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): Lancet 1998; 352:854–865.
104. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association. Diabetic neuropathies:a statement by the American Diabetes Association. Diabetes Care 2005;28:956–962.
105. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL Sr, Mueller MJ, Sheehan P, Wukich DK, American Diabetes Association, American Association of Clinical Endocrinologists. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008;31:1679–685.
106. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006;29:1300–1306.
107. Kitzmiller JL, Block JM, Brown FM, Catalano PM, Conway DL, Coustan DR, Gunderson EP, Herman WH, Hoffman LD, Inturrisi M, Jovanovic LB, Kjos SI, Knopp RH, Montoro MN, Ogata ES, Paramsothy P, Reader DM, Rosenn BM, Thomas AM, Kirkman MS. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:1060–1079.

108. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. *Am J Med* 2009;122:443–453.
109. Clark CM, Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG. A systematic approach to risk stratification and intervention within a managed care environment improves diabetes outcomes and patient satisfaction. *Diabetes Care* 2001; 24:1079–1086.
110. O'Connor PJ. Electronic medical records and diabetes care improvement: are we waiting for Godot? *Diabetes Care* 2003;26:942–943.
111. Davidson MB. How our current medical care system fails people with diabetes: lack of timely, appropriate clinical decisions. *Diabetes Care* 2009;32:370–372.
112. Ajit Auluck. Diabetes mellitus: an emerging risk factor for oral cancer? Debate and opinion. *JCDA*. 2007 ; 73(6) : 501-502.
113. Fushini H. The effect of parabiosis on serum and kidney glucosidase activities in spontaneous diabetic mice. *Diabetologica* 1980 ; 19(50) : 50-53.
114. Eduardo Jose Calderia, Progresso Jose Garcia, Elaine Minatel, Jose Angelo Cailli, Valeria Helena Alves Cagnon. *Braz. J. Morphol. Sci* 2004 ; 21(4) : 197-205.
115. Seema Hallikerimath, Gaurav Sapra, Alka Kale, PR Malur. Cytomorphometric analysis and assessment of Periodic Acid Schiff positivity of Exfoliated cells from apparently normal buccal mucosa of type 2 diabetic patients. *Acta Cytologica* 2010 ; 55 : 197-202.
116. Joseph L. Evans, Ira D Goldfine, Betty A Maddux and Gerold M. Grodsky: Are oxidative stress-Activated signaling Pathways mediators of insulin resistance and B-cell dysfunction?: *Diabetes* 2003 ; 52.

117. David B Ferguson. Text book of Oral Bioscience, 1st edition, Churchill Livingstone. An Imprint of Harcourt Publishers Limited.1999 publication. Printed in China.
118. Eliaz kaufman and Ira B .Jamster. The diagnostic applications of saliva - A review. Crit Rev Oral Biol Med 2002 ; 13(12) : 197-212
119. The diabetes control and complications trial research group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complication Trail JAMA 1996; 276: 1409-15.
120. American Diabetes Association consensus on self monitoring of blood glucose. Diabetes care 1987 ; 10 : 95-9.
121. Daneman D, Siminera L. The role of self monitoring of blood glucose in the routine management of children with insulin dependent diabetes mellitus. Diabetes care 1985 ; 8 : 1 -4.
122. Pohl SI, Gonder-Fredrick LA. Self measurement of blood glucose concentrations. Clinical significance of patient generated measurements. Diabetic care.1985;8:617-19.
123. <http://www.mydr.com.au/tests-investigations/diabetes-and-urine-glucose-monitoring>.
124. Siliva Chiappin, Giorgia Antonelli, Rasalba Gatti, Elio F De Palo. Saliva specimen : A new laboratory tool for diagnostic and basic investigation. Clinica Chimica Acto 2007 ; 383(12) : 30-40.
125. Proteomic Identification of Salivary Biomarkers of Type-2 Diabetes, Paturi V. Rao[‡], Ashok P. Reddy[‡], Xinfang Lu[‡], Surendra Dasari[‡], Adiraju Krishnaprasad[§], Evan Biggs[‡], Charles T. Roberts, Jr.[‡] and Srinivasa R. Nagalla, J. Proteome Res., 2009 ; 8(1), : 239–245

126. K. K. Mehrotra, T. N. Chawla, and A. Kumar. Correlation of salivary sugar with blood sugar. *Journal of the Indian Dental Association* 1968 ; 40(10) : 265–269.
127. C. O. Reuterving, G. Reuterving, E. H`agg, and T. Ericson. Salivary flow rate and salivary glucose concentration in patients with diabetes mellitus influence of severity of diabetes. *Diab`ete et M´etabolisme* 1987 ; 13(4) : 457–462.
128. P. Marchetti, M. Tognarelli, R. Giannarelli. Decreased salivary glucose secretory rate: usefulness for detection of diabetic patients with autonomic neuropathy. *Diabetes Research and Clinical Practice* 1989 ; 7(3) : 181–186.
129. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK et al. Diabetes epidemiology study group in Indian (DESI). High prevalence of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survey. *Diabetologia* 2001 ; 44 : 2094-101.
130. Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. *Diabetes Care* 2006; 29 : 1046-51.
131. Raz I, Wilson PW, Strojek K, Kowalska I,Bozиков V, Gitt AK, Jermendy G, Campaigne SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009;32:381–386.
132. Ana Carolina U, Vasconcelos, Maria Sueli M. Soares, Paulo C. Almeida and Teresa C. Soares. Comparative study of the concentration of salivary and blood glucose in type 2 diabetic patients. *Journal of Oral Science* 2010 ; 52(2) : 293-298. (No Title)

133. Shehla Amer, Mniza Yousuf, P.Q.R. Siddiqui and Junaid Alam. Salivary glucose concentrations in patients with diabetes mellitus – a minimally invasive technique for monitoring blood glucose levels. *Pakistan Journal of Pharmaceutical Sciences* 2001 ; 4(1) : 33-37.
134. Darwazeh AMG, MacFarlane T W, McCuish A, Lamey P J. Mixed salivary glucose levels and candidal carriage in patients with diabetes mellitus. *J Oral Pathol Med* 1991;20:280-283.
135. Murrah VA, Crusson JT, Sauk JJ. Parotid basement membrane in diabetes mellitus. *J Oral Pathology* 1985 ; 14 : 236-46.